Tu1740 – Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Maintenance Study
Gert A. Van Assche, Laurent Peyrin‐Biroulet(Délégation Centre-Est), Rupert W. Leong(The University of Sydney), Tadakazu Hisamatsu(Kyorin University), Silvio Danese(IRCCS Ospedale San Raffaele), Stephan R. Targan(Cedars-Sinai Medical Center), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), Christopher D. O’Brien(Cedars-Sinai Medical Center), Philippe Szapary(Cedars-Sinai Medical Center), Thomas Baker(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 1
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k